- What’s behind the proposed pullback on remote patient monitoringCompanies that help doctors keep tabs on their patients at home are freaking out after Medicare's proposal last week to gut remote patient monitoring, or RPM. The plan is a total about-face from…Endpoints · 1d ago↗ source
- Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansionPlus, news about Lonza, Bachem and Samsung Biologics. 🤝 Repligen to acquire BioLife Solutions: Repligen will pay around $1.5 billion for cell processing service supplier BioLife, 36% of which w…Endpoints · 1d ago↗ source
- Lilly's triple agonist heads to regulators after two more Phase 3 obesity winsRetatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer Eli Lilly said Thursday. The filing…